Cargando…

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study

BACKGROUND: Direct oral anticoagulants (DOACs) are the American Society of Hematology guideline-recommended treatment for venous thromboembolism (VTE) in the United States (US). AIM: To compare risk of VTE recurrence between patients who, following the first fill, discontinued (“one-and-done”) versu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alberts, Mark, Zhdanava, Maryia, Pilon, Dominic, Caron-Lapointe, Gabrielle, Lefebvre, Patrick, Bookhart, Brahim, Kharat, Akshay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366276/ https://www.ncbi.nlm.nih.gov/pubmed/37204616 http://dx.doi.org/10.1007/s11096-023-01589-7

Ejemplares similares

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study
por: Alberts, Mark, et al.
Publicado: (2023)

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation
por: Alberts, Mark, et al.
Publicado: (2023)

Extended anticoagulation after venous thromboembolism: should it be done?
por: Fernandes, Caio J., et al.
Publicado: (2019)

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
por: Salam, Tabassum, et al.
Publicado: (2023)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
por: Zhdanava, Maryia, et al.
Publicado: (2023)

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA
por: Pilon, Dominic, et al.
Publicado: (2022)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
por: Kavati, Abhishek, et al.
Publicado: (2018)

Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
por: Zhdanava, Maryia, et al.
Publicado: (2020)

Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism
por: Laliberté, François, et al.
Publicado: (2013)

Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
por: Zhdanava, Maryia, et al.
Publicado: (2021)

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
por: Williams, Paul V., et al.
Publicado: (2018)

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Streiff, Michael B., et al.
Publicado: (2018)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
por: Zhdanava, Maryia, et al.
Publicado: (2021)

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
por: Lefebvre, Patrick, et al.
Publicado: (2012)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Acute on Chronic Venous Thromboembolism on Therapeutic Anticoagulation
por: Bassi, Byron, et al.
Publicado: (2013)

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: Kim, Joo Hee, et al.
Publicado: (2017)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
por: Berger, Jeffrey S., et al.
Publicado: (2022)

Current Status of New Anticoagulants in the Management of Venous Thromboembolism
por: Montoya, Roberto C., et al.
Publicado: (2012)

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism
por: Fareed, Jawed, et al.
Publicado: (2011)

The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants
por: Blann, Andrew D, et al.
Publicado: (2009)

Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
por: Moodley, Otto, et al.
Publicado: (2015)

Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients
por: Lutsey, Pamela L., et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_89tjknslhoefp97auqqa117q80